1. Introduction {#sec1}
===============

Our research has had a focus on nicotinic acetylcholine receptors (nAChRs) of parasitic nematodes because they are target sites that bind a major class of anthelmintic drugs. nAChRs are pentameric ligand-gated ion channels involved in synaptic transmission in the nervous systems of both vertebrates and invertebrates ([@bib21]); these receptor channels also serve other functions including paracrine functions in non-excitable tissues ([@bib17]). The nAChRs are activated by the ligand agonists: acetylcholine (ACh), nicotine and structurally related derivatives, that produce opening of their transmembrane ion-channel and flux of sodium, potassium and sometimes calcium ions across the membrane.

The agonist-binding sites of nAChRs have been well studied by photolabeling, mutagenesis and electrophysiology ([@bib2]). Our understanding of ligand-receptor interactions has improved following co-crystal structure studies of invertebrate acetylcholine binding proteins (AChBPs) with cholinergic ligands ([@bib20], [@bib19]). AChBPs are homologs of the extracellular agonist-binding site domain of nAChRs that share 20--24% nucleotide sequence identity with the extracellular domain of AChRs ([@bib5]). The agonist-binding site of nAChRs is in the extracellular domain at the interface between the principal subunit (that is an alpha subunit with vicinal cysteines) and the adjacent complementary subunit. Five aromatic amino acids in the agonist-binding site are highly conserved in nAChRs, some of which contribute to the cation-π interactions with the cationic nitrogen in agonists ([@bib10]). Another feature of nAChR agonists is the hydrogen bond acceptor, which is about 4--6 Å from the cationic nitrogen. Based on the high-resolution structures of AChBPs, the hydrogen bond acceptor of the agonist is stabilized by a water molecule, which interacts with the carbonyl or the amide backbones of two less conserved residues (L102 and M114) on loop E of the complementary subunit through three hydrogen bonding interactions ([@bib24]).

*Ascaris*, a genus of clade III nematode parasites, are gastrointestinal roundworms that infect humans, pigs and other animals worldwide ([@bib22]) and have been estimated to cause more than 1.2 billion human infections ([@bib9]). In developing countries, the control of *Ascaris* infection relies on the limited number of available anthelmintic drugs. Drug resistance in various nematodes has been reported following frequent use of anthelmintics ([@bib11]). There is an unmet need for novel effective drugs which would overcome development of resistance to existing anthelmintics.

The ACR-16 nicotinic acetylcholine receptor of *Ascaris suum* (*Asu-*ACR-16) is a nematode homopentameric receptor, which resembles vertebrate α7 nAChRs ([@bib16]). *Asu-*ACR-16 is widely distributed in *A. suum* tissues but its physiological function remains to be determined ([@bib1], [@bib26]). As one of the recently characterized nematode parasitic nAChRs, *Asu-*ACR-16 is pharmacologically different to its host α7 nAChR and may be exploited as an anthelmintic drug target to counter resistance to cholinergic anthelmintics directed at other pharmacological types of nAChR ([@bib12], [@bib26]).

The agonist-binding site of *Asu-*ACR-16 receptors can be predicted by homology modeling using the human α7 nAChR chimera as structural template, which shares 38% identity and 73% similarity in amino acid sequence. Five conserved aromatic residues and two hydrogen-bond interacting residues have orientations very close to corresponding residues in other nAChRs, facilitating our investigation of drug-receptor interactions of the *Asu-*ACR-16 receptor ([@bib26]).

We know that the *Asu-*ACR-16 receptor is sensitive to six nicotinic agonists: nicotine, ACh, cytisine, 3-bromocytisine, epibatidine, dimethyl-4-phenyllpiperazinium iodide (DMPP), but insensitive to other cholinergic anthelmintic agonists ([@bib1]). All six of the *Asu-*ACR-16 agonists share the nicotinic pharmacophore: a cationic nitrogen separated by ∼5 Å from a hydrogen bond acceptor. Here we use a combination of structural modeling and synthetic strategy based on the nicotinic pharmacophore to explore the pharmacological profiles of nicotine derivatives on the *Asu-*ACR-16 receptor.

2. Materials and methods {#sec2}
========================

2.1. Homology modeling and docking {#sec2.1}
----------------------------------

The *Asu*-ACR-16 sequence is available in UniProtKB under the accession number F1KYJ9 ([@bib25]). Three crystal structures of a human α7 nAChR chimera co-crystalized with ligands of different modes of action were used as templates ([Table 1](#tbl1){ref-type="table"}) to build three different bound-form models of the ECD-*Asu-*ACR-16 ([@bib14], [@bib13], [@bib26]). Smiles strings of nicotine derivatives were obtained from the ZINC website (<http://zinc.docking.org/search/structure>) and converted to PDBQT format for our docking studies. Docking of these ligands was performed at the orthosteric ligand-binding sites of agonist-bound, apo (no ligand) and antagonist-bound forms of the ECD*-Asu*-ACR-16 models using AutoDock Vina Software ([@bib23], [@bib26]). We investigated the intermolecular interactions in our models by comparing the intermolecular distances in the crystal structures and our models (≤ 1 Å difference).

2.2. Expression and electrophysiology of Asu-ACR-16 in oocytes {#sec2.2}
--------------------------------------------------------------

Full length cRNA of *Asu*-*acr-16* and the ancillary gene, *Asu*-*ric-3* (UniProtKB accession number: F1L1D9_ASCSU). were prepared using the previously described methods ([@bib26]). A cRNA mixture of 25 ng *Asu-acr-16* and 5 ng *Asu-ric-3* cRNA in 50 nL RNAse-free water was injected into de-folliculated *Xenopus laevis* oocytes (Ecocyte Bioscience, Austin, TX, USA). The injected oocytes were incubated in incubation solution (100 mM NaCl, 2 mM KCl, 1.8 mM CaCl~2~·2H~2~O, 1 mM MgCl~2~·6H~2~O, 5 mM HEPES, 2.5 mM Na pyruvate, 100 U/mL penicillin, 100 μg/mL streptomycin, pH 7.5) at 19 °C for 4--8 days, with 100 μM BAPTA-AM added ∼3 h before recording.

A two-electrode voltage-clamp technique was used to record currents from the *Asu*-ACR-16 receptor expressed in the *Xenopus* oocytes. The oocytes were kept in recording solution (100 mM NaCl, 2.5 mM KCl, 1 mM CaCl~2~·2H~2~O and 5 mM HEPES, pH 7.3) and clamped to −60 mV. Inward currents were induced by addition of chemicals that acted as agonists that opened the nicotinic ion-channel receptors. An Axoclamp 2B amplifier (Molecular Devices, CA, and USA) was used to record the currents that were acquired with Clampex 9.2 (Molecular Devices, CA, USA) software and analyzed using GraphPad Prism 5.0 (GraphPad Software Inc. CA, USA).

2.3. Chemicals used for synthesis {#sec2.3}
---------------------------------

The following chemicals were used for the synthesis of (S)-5-bromonicotine, (S)-5-bromoanabsine and (S)-5-ethynyl-anabsine: 4,4'-di-*tert*-butyl-2,2'-dipyridyl (dtbpy), copper (II) bromide (CuBr~2~), 2-methyl-3-butyn-2-ol, triethylamine (Et~3~N) and *N*,*N*-diisopropylethylamine (DIPEA) obtained from Sigma-Aldrich (St Louis, MO, USA); di-μ-methoxobis (1,5-cyclooctadiene)diiridium(I) (\[Ir(COD) (OMe)\]~2~) and methanesulfonato (2-di-t-butylphosphino-2′,4′,6\'-tri-i-propyl-1,1\'-biphenyl) (2\'-amino-1,1\'-biphenyl-2-yl)palladium (II) (Pd(PPh~3~)~2~Cl~2~) obtained from Strem Chemicals (Newburyport, MA, USA); (S)-nicotine, (S)-anabasine and copper(I) iodide (CuI) obtained from Alfa Aesar (Ward Hill, MA, USA); bis(pinacolato)diboron (B~2~pin~2~) obtained from Matrix Scientific (Columbia, SC, USA); (trimethylsilyl)acetylene and di-*tert*-butyl dicarbonate (Boc~2~O) obtained from Oakwood Products (Estill, SC, USA); dichloromethane (DCM), trifluoroacetic acid (TFA), methanol (MeOH), tetrahydrofuran (THF) and potassium carbonate (K~2~CO~3~) obtained from Fisher Scientific (Waltham, MA, USA).

2.4. General synthetic experiment {#sec2.4}
---------------------------------

All air-sensitive procedures were conducted under an inert atmosphere of a nitrogen-filled dry box or by standard Schlenk techniques. All reactions were performed under an atmosphere of nitrogen unless otherwise stated. All glassware for moisture sensitive reactions was dried at 140 °C in an oven. THF and DCM were degassed by purging with argon for 45 min and dried with a solvent purification system by passing through a one-meter column of activated alumina. Flash column chromatography was performed on Fisher brand silica gel 60 (230--400 mesh). Products were visualized on TLC by UV light or by staining with KMnO~4~, phosphomolybdic acid or ceric ammonium molybdate. HRMS (ESI) analysis was performed at the Iowa State University Chemical Instrumentation Facility on an Agilent 6540 QTOF spectrometer. NMR spectra were acquired on Varian MR-400 and Bruker Avance III 600 spectrometers at the Iowa State University Chemical Instrumentation Facility. Chemical shifts are reported in ppm relative to a residual solvent peak (CDCl~3~ = 7.26 ppm for ^1^H and 77.0 ppm for ^13^C). Coupling constants are reported in hertz.

2.5. Synthesis of (S)-5-bromonicotine {#sec2.5}
-------------------------------------

Synthesis of (S)-5-bromonicotine was carried out following the published procedure ([@bib15]):

2.6. Synthesis of (S)-*tert*-butyl-2-(pyridine-3-yl)piperidine-1-carboxylate {#sec2.6}
----------------------------------------------------------------------------

Synthesis of compound **-1**, (*S*)-*tert*-butyl 2-(pyridin-3-yl)piperidine-1-carboxylate, below, was conducted using the following approach.

Boc~2~O (3.30 g, 15.1 mmol, 1.10 equiv) was added to a solution of (S)-anabasine (2.23 g, 13.7 mmol, 1.0 equiv) and Et~3~N (2.10 mL, 15.1 mmol, 1.10 equiv) in THF at 0 ^°^C. The reaction mixture was stirred for 10 min and warmed to room temperature. After stirring for 2 h, the mixture was diluted with water, and extracted with EtOAc (3×). The organic layers were combined, dried over Na~2~SO~4~ and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel (1:1 hexane:EtOAc) to yield compound −1, (*S*)-*tert*-butyl 2-(pyridin-3-yl)piperidine-1-carboxylate in 95% yield (3.40 g, 13.1 mmol) as a pale yellow liquid (confirmed by ^1^H NMR (CDCl~3~, 400 MHz) δ 1.36--1.69 (m, 4H), 1.46 (s, 9H), 1.91--2.00 (s, 1H), 2.27 (d, *J* = 14.0 Hz, 1H), 2.69--2.76 (m, 1H), 4.07 (d, *J* = 14.8 Hz, 1H), 5.47 (br, s, 1H), 7.34--7.38 (m, 1H), 7.63 (d, *J* = 7.6 Hz, 1H), 8.50 (s, 1H), 8.52 (s, 1H): spectral data matched the literature precedent, ([@bib3]).

2.7. Synthesis of (S)-*tert*-butyl 2-(5-bromopyridin-3-yl)piperidine-1-carboxylate {#sec2.7}
----------------------------------------------------------------------------------

Synthesis of compound **-2,** (S)-*tert*-butyl 2-(5-bromopyridin-3-yl)piperidine-1-carboxylate from compound −1 was carried out as described below.

In a nitrogen-filled glove box, compound **-1** (1.31 g, 5.0 mmol), B~2~pin~2~ (1.12 mg, 4.4 mmol), \[Ir(COD) (OMe)\]~2~ (99.5 mg, 0.150 mmol, 0.030 equiv), dtbpy (80.5 mg, 0.030 mmol, 0.060 equiv), and THF (8.0 mL) were combined in a vial. The reaction mixture was then sealed and heated at 80 °C for 16 h. After the reaction mixture was cooled to room temperature, the volatiles were removed under vacuum. The residue was dissolved in 50.0 mL of MeOH and 50.0 mL of distilled water followed by CuBr~2~ (3.35 g, 15.0 mmol). The flask was then sealed and heated at 80 °C for 16 h. The reaction mixture was cooled to room temperature, and 30% NH~4~OH (aq) (20.0 mL) was added to the reaction mixture. The reaction mixture was extracted with EtOAc (3 ×), and the organic layers were combined, washed with brine, and dried over Na~2~SO~4~. The product was purified by column chromatography using silica gel (3:1 hexane:EtOAc) to give compound **-2**, (*S*)-*tert*-butyl 2-(5-bromopyridin-3-yl)piperidine-1-carboxylate in 36% yield (618 mg, 1.80 mmol) as a pale yellow solid. ^1^H NMR (400 MHz, CDCl~3~) δ 1.30--1.69 (m, 4H), 1.46 (s, 9H), 1.89--1.98 (s, 1H), 2.24 (dd, *J* = 16.0, 2.0 Hz, 1H), 2.68--2.75 (m, 1H), 4.07 (d, *J* = 15.6 Hz, 1H), 5.43 (s, 1H), 7.69 (s, 1H), 8.42 (s, 1H), 8.56 (s, 1H); ^13^C NMR (100.5 MHz, CDCl~3~) δ 19.2, 25.0, 27.7, 28.3, 40.2, 51.2, 80.2, 120.9, 137.1, 138.1, 146.4, 148.8, 155.2; HRMS (ESI) calcd. For C~15~H~22~BrN~2~O~2~^+^ \[M+H\]^+^ 341.0859, found 341.0864, [Fig. S1](#appsec1){ref-type="sec"}.

2.8. Synthesis of (S)-5-bromoanabasine {#sec2.8}
--------------------------------------

Synthesis of (S)-5-bromoanabasine, was prepared from compound **-2** as described below.

To a solution of compound **2** (93.0 mg, 0.273 mmol, 1.0 equiv) in DCM (5.0 mL), TFA (1.0 mL) was added dropwise. The reaction mixture was stirred at room temperature for 12 h. The mixture was diluted with saturated NaHCO~3~ and extracted with EA (3×). The organic layers were combined, dried over Na~2~SO~4~ and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel (10:1 hexane:EtOAc to 10:1 EtOAc:Et~3~N) to give (S)-5-bromoanabasine in 83% yield (54.4 g, 0.226 mmol) as a pale yellow solid. ^1^H NMR (400 MHz, CDCl~3~) δ 1.43--1.55 (m, 3H), 1.65--1.68 (m, 1H), 1.75--1.78 (m, 1H), 1.89 (brs, 2 H), 2.74--2.80 (m, 1H), 3.18 (d, *J* = 11.6 Hz, 1H), 3.61--3.63 (m, 1H), 7.89 (t, *J* = 1.6 Hz, 1H), 4.7 (d, *J* = 1.6 Hz, 1H), 8.53 (d, *J* = 2.0 Hz, 1H); ^13^C NMR (151.0 MHz, CDCl~3~) δ 25.0, 25.5, 34.8, 47.4, 59.1, 120.8, 136.9, 142.5, 146.7, 149.6; HRMS (ESI) calcd. For C~10~H~14~BrN~2~^+^ \[M+H\]^+^ 241.0335, found 241.0332, [Fig. S2](#appsec1){ref-type="sec"}.

2.9. Synthesis of (S)-5-ethynyl-anabasine {#sec2.9}
-----------------------------------------

Synthesis of (S)-5-ethynyl-anabasine, was prepared from (S)-5-bromoanabasine as described below.

In a nitrogen-filled Schlenk tube, compound **2** (247 mg, 1.02 mmol) in THF (3.0 mL), Pd(PPh~3~)~2~Cl~2~ (143 mg, 0.204 mmol, 0.20 equiv), CuI (39.0 mg, 0.204 mmol, 0.20 equiv), DIPEA (3.0 mL), and trimethylsilylacetylene (0.16 mL, 1.12 mmol, 1.10 equiv) were added. The mixture was stirred at 70 °C for 16 h. After cooled to room temperature, the mixture was filtered through a short pad of silica gel and washed with ethyl acetate The filtrate was concentrated and purified by short silica gel column (100:1 hexane:EtOAc to hexane:EtOAc 5:1) to give the crude product, which was used directly for next step.

To a solution of the crude product in DCM (10.0 mL), TFA (10.0 mL) was added. The mixture was stirred at rt for 2 h. All the volatiles were removed under reduced pressure. The crude product was purified by short silica gel column (2:1 hexane:EtOAc to 8:1 EtOAc:Et~3~N).

To a solution of the above crude product in MeOH (10.0 mL), K~2~CO~3~ (568 mg, 4.08 mmol) was added. The mixture was stirred at room temperature for 16 h. After filtration and concentration, the product was purified by column chromatography using silica gel (5:1 hexane:EtOAc to 10:1 EtOAc:Et~3~N) to give **(S)-5-ethynyl-anabasine** in 7% yield (12.8 mg, 0.0714 mmol) as a pale yellow liquid. ^1^H NMR (400 MHz, CDCl~3~) δ 1.45--1.57 (m, 3H), 1.66--1.69 (m, 1H), 1.77--1.79 (m, 1H), 1.90 (brs, 1H), 2.07 (brs, 1H), 2.76--2.81 (m, 1H), 3.18 (s, 1H), 3.19 (d, *J* = 12.0 Hz, 1H), 3.62--3.65 (m, 1H), 7.84 (t, *J* = 2.0 Hz, 1H), 8.54 (s, 1H), 8.59 (s, 1H); HRMS (ESI) calculated. For C~12~H~15~N~2~^+^ \[M+H\]^+^187.1230, found 187.1232, [Fig. S3](#appsec1){ref-type="sec"}.

2.10. Pharmacological characterization of nicotinic derivatives and data analysis {#sec2.10}
---------------------------------------------------------------------------------

The aqueous soluble compounds: acetylcholine (ACh), (S)-nicotine, (S)---SIB 1508Y, (S)-1-methylnicotinium, (S)-1'-methylnicotinium, nornicotine, (S)-cotinine, (S)-anabasine, (S, R)-anabasine were dissolved in recording solution at the concentrations described in the results. Non-polar compounds were dissolved initially in DMSO to make 100 mM stock solutions of each. Subsequently they were diluted in recording solution to give a concentration of DMSO of \<0.1%.

100 μM ACh was applied first to each oocyte for 10 s to check for robust *Asu*-ACR-16 expression. In all oocyte recordings the peak current response to 100 μM ACh was used to normalize subsequent current responses in that oocyte. Recording solution was then used to wash out the drug from the oocytes for 3 min prior to next application of drug perfusion.

Nicotine derivatives that elicited inward currents at 100 μM were classed as agonists. To further characterize the nicotine derivative agonists, increasing concentrations of the derivatives were applied for 10 s (3 min wash intervals between drug applications). The resulting dose-response relationships were described by the Hill equation to give estimates of the *EC*~*50*~ (μM), Hill slope (*n*~*H*~*)*, maximum response (*I*~max~, %) and expressed as mean ± S.E.M. (*N* = 5) using GraphPad Prism 5.0 (Graphpad Software Inc. CA, USA).

2.11. Drugs {#sec2.11}
-----------

ACh, (−)-nicotine hydrogen tartrate salt ((S)-nicotine), anabasine ((S, R)-anabasine), (±)-nornicotine (nornicotine), 5-(1-methyl-pyrrolidin-2-yl)-pyridin-2-ylamine dihydrochloride (6-AN) and (−)-cotinine ((S)-cotinine) were purchased from Sigma-Aldrich (St Louis, MO, USA). SIB 1508Y maleate ((S)---SIB 1508Y) was obtained from Tocris Bioscience (Ellisville, MO, USA). (S)-anabasine, rac-5-methylnicotine (5-methylnicotine), S-(−)-nicotine-5-carboxaldehyde ((S)-nicotine-5-carboxaldehyde), (±)-6-methylnicotine (6-methylnicotine), (S)-1-methylnicotinium iodide ((S)-1-methylnicotinium), (S)-1'-methylnicotinium iodide ((S)-1'-methylnicotinium), (R, S)---N-ethyl nornicotine (homonicotine), N-methyl anabasine were purchased from Toronto Research Chemicals (Toronto, ON, Canada).

3. Results {#sec3}
==========

3.1. Ligand-binding sites {#sec3.1}
-------------------------

*Lst*-AChBP (PDB code: [1UW6](pdb:1UW6){#intref0015}) ([@bib6]) shows 23.33% sequence identity and 64.29% sequence similarity to ECD-*Asu*-ACR-16 ([Fig. S4](#appsec1){ref-type="sec"}A) and is the only crystal structure of a protein homologous to *Asu-*ACR-16 co-crystalized with nicotine to date. The ligand-binding site for agonist is at the interface between the principal side and the complementary side in two adjacent subunits of nAChRs ([@bib14], [@bib18]).

Nicotine adopts the same binding pose in all five ligand-binding sites in *Lst*-AChBP pentamer ([Fig. 1](#fig1){ref-type="fig"}A). The pyrrolidine ring of nicotine is oriented toward the basal side of the binding site on the principal subunit, whereas the pyridine ring faces the apical side on the complementary subunit. The protonated nitrogen (N2) in the pyrrolidine ring of nicotine is involved in cation-π interactions, mainly with W143 (on principal subunit) or maybe four aromatic residues in the binding site (principal subunit: Y89, Y185, Y192; complementary subunit: W53) ([Fig. 1](#fig1){ref-type="fig"}B). The N2 is also hydrogen-bonded to the hydroxyl moiety of Y89 and W143 carbonyl backbone. Hydrophobic interactions from disulfide-bonded C187 and C188 on loop C stabilize nicotine in the binding pocket. The pyridine ring nitrogen of nicotine (N1) is hydrogen-bonded to a water molecule, which is stabilized by the carbonyl backbone of L102 and M114 amide backbone of the complementary subunit ([Fig. 1](#fig1){ref-type="fig"}B) ([@bib6], [@bib24]).

[Fig. 1](#fig1){ref-type="fig"}C shows the ligand-binding site of the agonist-bound *Asu*-ACR-16 dimer viewed from the same angle as [Fig. 1](#fig1){ref-type="fig"}B. The residues involved in the binding site are highlighted in [Fig. 1](#fig1){ref-type="fig"}C and indicated in [Fig. S4](#appsec1){ref-type="sec"}A by arrows. The interacting residues in the binding site of the agonist-bound *Asu*-ACR-16 model share similar orientations with those in the binding site of *Lst*-AChBP. The hydrophobic, hydrogen-bond and van der Waals contacts between nicotine and AChBP were therefore predicted in *Asu*-ACR-16. Y117, W173, Y214, Y221 from principal and W79 from complementary constitute the aromatic cage, in which W173 contributes most to the cation-π interaction with protonated tertiary amine or tetramethyl ammonium salt of nicotine or its derivatives. The hydroxyl moiety of Y117 and W173 carbonyl backbone are hydrogen-bonded to the protonated tertiary amine or ammonium of the ligand. The carbonyl backbone of N131 and I143 amide backbone from the complementary face have water-mediated hydrogen bond with the pyridine ring N1 of the ligand.

Structural superimposition of the binding-site residues among three different bound forms Asu-ACR-16 show details of conformational changes of residues when the agonist is in the binding pocket of the receptor. Of particular note is the inward movement of vicinal cysteines toward pyrrolidine N2 of nicotine. The antagonist-bound model has less steric hindrance in the open receptor binding site ([Fig. 1](#fig1){ref-type="fig"}D) ([@bib13]).

The human α7 nAChR chimera (PDB code: [3SQ6](pdb:3SQ6){#intref0020}) ([@bib14]) shows 62.98% sequence identity and 80.29% nucleotide sequence similarity with the extracellular domain of human α7 nAChR (UniProtKB accession number: P36544). The residues constituting the ligand-binding site are highly conserved between human α7 nAChR chimera and human α7 nAChR ([Fig. S4](#appsec1){ref-type="sec"}B). The crystal structure of human α7 nAChR chimera co-crystalized with epibatidine could be used to study the binding site of agonist-bound human α7 nAChR. Comparison of the binding sites in *Lst-*AChBP ([Fig. 2](#fig2){ref-type="fig"}A), human α7 nAChR chimera ([Fig. 2](#fig2){ref-type="fig"}B), agonist-bound *Asu*-ACR-16 ([Fig. 2](#fig2){ref-type="fig"}C) and apo form of *Asu*-ACR-16 ([Fig. 2](#fig2){ref-type="fig"}D) reveals that the 5-substituted pyridine derivatives of nicotine would be favorable, with more space for the binding site of the ECD-*Asu*-ACR-16, but not for the human α7 nAChR. The black dotted arrows mark the likely orientation of the functional group on the 5-pyridine moiety of nicotine ([Fig. 2](#fig2){ref-type="fig"}C and D). Additionally, our docking results show that the 5-substituted pyridine ring approaches close to the disulfide bonds of *Asu*-ACR-16 and that the pyrrolidine ring is twisted downward in the binding site ([Fig. S5](#appsec1){ref-type="sec"}).

3.2. Potency of nicotine derivatives {#sec3.2}
------------------------------------

Initially we tested a range of nicotine analogues (compounds labelled 3--5 & 7--17 in [Table 2](#tbl2){ref-type="table"}, [Fig. 3](#fig3){ref-type="fig"}) as agonists to further characterize the pharmacological profile of *Asu-*ACR-16 receptors by measuring agonist *EC*~*50*~, *I*~max~ and *n*~*H*~ values. *The EC*~*50*~ for (S)-nicotine was 6.21 ± 0.56 μM and the *I*~max~ was 82.39 ± 2.52%, *N* = 5 ([Table 2](#tbl2){ref-type="table"}). (S)-nicotine is a potent agonist of *Asu*-ACR-16, but can also activate mammalian nAChRs and as an anthelmintic would also cause effects in the host ([@bib7]). As a low-molecular-weight and water soluble molecule, (S)-nicotine was selected as our initial lead for further optimization ([@bib4]). Using (S)-nicotine as a pharmacophore and the predicted three-dimensional structures of the *Asu*-ACR-16 ligand-binding site, we studied structure-activity relationships by measuring the *EC*~*50*~, *I*~max~ and *n*~*H*~ values of the nicotine derivatives ([Fig. 4](#fig4){ref-type="fig"}, [S6](#appsec1){ref-type="sec"} and [Table 2](#tbl2){ref-type="table"}) on the *Asu-*ACR-16 receptor. The agonist dose-response relationships for ACh and (S)-nicotine ([Fig. 5](#fig5){ref-type="fig"}A), pyridine substituted nicotine derivatives ([Fig. 5](#fig5){ref-type="fig"}B) and the pyrrolidine substituted nicotine derivatives ([Fig. 5](#fig5){ref-type="fig"}C) are shown. The pyridine N1 methylated substituent \[(S)-1-methylnicotium\], the 5'-carbonylated pyrrolidine substituent \[(S)-cotinine\], and the piperidine N2 methylated substituent \[N-methyl anabasine\] did not act as agonists.

3.3. (S)-enantiomers are more potent {#sec3.3}
------------------------------------

We compared the pharmacological profiles of (S)-anabasine and its racemic mixture on *Asu-*ACR-16 ([Fig. S7](#appsec1){ref-type="sec"}). The *EC*~*50*~ of (S)-anabasine was significantly lower than the *EC*~*50*~ of its racemic mixture (*P* \< 0.05, *N* = 5). The *I*~max~ of (S)-anabasine was slightly higher than that of its racemic mixture (*P* \> 0.05, *N* = 5). These results are consistent with other published results that illustrate the higher intrinsic activities of (S)-enantiomer nicotine alkaloids rather than their (R)-enantiomer ([@bib8]). Therefore, subsequent synthesis of compounds was directed towards preparation of (S)-enantiomers.

3.4. (S) -5-ethynyl-anabasine, (S)-5-bromoanabasine and (S)-5-bromonicotine {#sec3.4}
---------------------------------------------------------------------------

Examination of the structures and *EC*~*50*~ potencies of (S)---SIB 1508Y and (S)-anabasine suggested that a novel compound, (S)-5-ethynyl-anabasine, would yield a more potent agonist. Consequently, it was synthesized, as described in the methods, along with (S)-5-bromonicotine and (S)-5-bromoanabsine that were produced during its synthesis. The three novel synthesized compounds were then tested on the *Asu*-ACR-16 receptor. The concentration response plots for these compounds revealed that two of the novel compounds, (S)-5-ethynyl-anabasine and (S)-5-bromoanabsine were the most potent agonists tested to date ([Fig. 5](#fig5){ref-type="fig"}C & [Table 2](#tbl2){ref-type="table"}).

3.5. Agonist rank order potency {#sec3.5}
-------------------------------

[Fig. 5](#fig5){ref-type="fig"} shows the dose-response plots for the most potent agonists. The rank order of potency the agonists based on the *EC*~*50*~ values, [Table 2](#tbl2){ref-type="table"}, was: (S)-5-ethynyl-anabasine \> (S)-5-bromoanabasine ≈ (S)---SIB 1508Y \> 5-methylnicotine ≈ (S)-anabasine \> (S)-5-bromonicotine \> 6-methylnicotine ≈ (S)-nicotine ≈ ACh \> (S)-1'-methylnicotinium ≈ (S)-nicotine-5-carboxaldehyde ≈ 6-AN \> homonicotine ≈ nornicotine. Two piperidine ring derivatives: (S)-5-bromoanabasine and (S)-anabasine, two 5-substituted pyridine derivatives: (S)---SIB 1508Y and 5-methylnicotine were more potent than ACh and (S)-nicotine (*P* \< 0.05, *N* = 5). The *EC*~*50*~ of the novel lead compound, (S)-5-ethynyl-anabasine, is 44 times lower (more potent) than its initial pharmacophore, (S)-nicotine, and is the most potent agonist of *Asu-*ACR-16.

3.6. Correlation between affinity and potency among nicotine derivatives {#sec3.6}
------------------------------------------------------------------------

The binding affinities of the selected nicotine derivatives were calculated for ligands docking into the agonist-binding site in the agonist-bound form, the apo (no ligand) form and the antagonist-bound form ECD-*Asu-*ACR-16 models. We examined the relationship between the binding affinities and the observed values of the expressed receptors for the *EC*~*50*~ (μM) of the nicotine derivatives. There was a positive correlation (+0.66) between the binding affinity and the *EC*~*50*~ of the apo form model (*P* \< 0.05) ([Fig. 6](#fig6){ref-type="fig"}); the correlation with the agonist bound *Asu-*ACR-16 (0.36) and antagonist bound *Asu-*ACR-16 (0.46) were smaller and did not reach statistical significance (*P* \> 0.05). The highest correlation with the apo form suggests that this model is more likely to predict the potency of unknown agonists than the other models of the receptor.

4. Discussion {#sec4}
=============

4.1. Structure-activity relationships of nicotine derivatives on *Asu*-ACR-16 {#sec4.1}
-----------------------------------------------------------------------------

### 4.1.1. Pyridine ring substituted derivatives {#sec4.1.1}

We studied the effects of functional groups added to the different positions of pyridine moiety of nicotine: the methyl group substituted at the 5- or 6- or N-pyridine moiety of nicotine, and an amino group substituted at the 6-pyridine moiety of nicotine. 5-Methylnicotine was the most potent agonist, while 6-methylnicotine was slightly less potent. 6-AN showed little agonist activity. The electron-donating group of the methyl or the amino at the 5- or 6-pyridine increased the electronegativity and alkalinity of the pyridine N1, and so stabilized the water-mediated hydrogen bond with the carbonyl backbone of N131 and I143 amide backbone from the complementary subunit of the receptor. The lone pair electrons on the pyridine N1 of (S)-1-methylnicotinium were replaced by the methyl group. As a result N1 cannot hydrogen-bond with the carbonyl backbone of N131 and I143 amide backbone from the receptor so that this reduces the intrinsic activity of N-pyridine substituted derivatives.

### 4.1.2. 5-substituted pyridine derivatives {#sec4.1.2}

Given that the electron-donating groups at the 5-pyridine of nicotine were found to have the highest potency as agonists, the electron-withdrawing groups of acetylene, bromine or aldehyde derivatives at the 5-pyridine position of nicotine were selected for testing. (S)---SIB 1508 was the most potent agonist, while (S)-5-bromonicotine and (S)-nicotine-5-carboxaldehyde were less potent. The extra cavity within the binding site of *Asu*-ACR-16 agonist-bound and apo model could accommodate the linear acetylene substituent and globular bromine atom at the 5-pyridine ring of nicotine, allowing the ligands to extend into unoccupied space ([Fig 2](#fig2){ref-type="fig"}CD, top left quadrants of the binding pocket). The bent structure of aldehyde appears to be less favored in the binding pocket. Our docking studies show another possible reason for the 5-substituted pyridine derivatives to stabilize *Asu*-ACR-16. [Fig. S5](#appsec1){ref-type="sec"}B&C show that the 5-substituted pyridine ring approaches towards the close-in conformation of the vicinal cysteines, which is a typical feature of the activated state of AChRs.

### 4.1.3. Pyrrolidine ring substituted derivatives {#sec4.1.3}

To study the effects of functional groups added to the different positions of pyrrolidine moiety of nicotine, a methyl or ethyl group was added at the N-pyrrolidine moiety of nicotine, and a ketone group was added at the 5'-pyrrolidine moiety of nicotine. The additional methyl group linked to the pyrrolidine N2 of (S)-1'-methylnicotinium produces a quaternary ammonium, which increases the cation-π interaction with the five aromatic residues from the ACR-16 receptor, but increases the steric hindrance around the pyrrolidine N2 making this compound stereochemically unfavorable. The increased steric hindrance due to the ethyl group at pyrrolidine N2 of homonicotine may be the reason for its reduced agonist potency. The secondary amine of nornicotine reduces the alkalinity and the probability of making a cation-π interaction with the receptor. The conjugative effect of the lone pair of electrons on the pyrrolidine N2 of (S)-cotinine to the π bond of carbonyl group, causes the pyrrolidine N2 to be hardly protonated, which significantly limits the cation-π interaction with the aromatic cage from the receptor and its action as an agonist.

### 4.1.4. Piperidine ring derivatives {#sec4.1.4}

The N-methyl pyrrolidine moiety was replaced by an N-methyl piperidine ring in nicotine structure to study the effect of increasing the membrane ring on the stimulatory activity of *Asu-*ACR-16. We found that N-methyl anabasine was inactive, but when the N-methyl group of the piperidine moiety was removed, the compound was a potent agonist. The piperidine ring of (S)-anabasine may have sterically and electrostatically stabilized the aromatic cage on the receptor better than the N-methylated pyrrolidine ring of nicotine. The novel lead compound, (S)-5-ethynyl-anabasine contains two moieties favorable to the *Asu-*ACR-16 ligand-binding site: an electron-withdrawing group at the 5-pyridine of nicotine moiety ((S)---SIB 1508Y) and; the piperidine moiety ((S)-anabasine). (S)-5-ethynyl-anabasine shows high potency (*EC*~*50*~ 0.14 ± 0.01 μM, *N* = 5) as an agonist.

4.2. Docking study as a probe for searching potent *Asu-*ACR-16 agonist {#sec4.2}
-----------------------------------------------------------------------

The potency (*EC*~*50*~) of the selected nicotinic alkaloids was correlated more with the binding affinity in the apo model of *Asu-*ACR-16 than with the agonist- or antagonist-bound model of *Asu*-ACR-16. This appears to be due to the different conformation changes of vicinal cysteines or the opened-up orientation of W79 in the agonist-bound and antagonist-bound models of *Asu-*ACR-16, which reduces the cation-π interaction between W79 and nicotine N2 ([@bib5], [@bib24]). The statistical correlation between the predicted ligand binding affinities in the apo model of *Asu-*ACR-16 and their corresponding potencies (*EC*~*50*~), suggests that the apo model would be more helpful when searching for potent agonists by docking.

5. Conclusion {#sec5}
=============

We used structural models of the ECD-*Asu-*ACR-16 agonist-binding site and expressed receptor to study the structure-activity relationships of several nicotine alkaloids on *Asu-*ACR-16 receptor. We synthesized a novel compound, (S)-5-ethynyl-anabasine, which was 44 times more potent than (S)-nicotine as an *Asu-*ACR-16 agonist. Our structure-based drug discovery of ACR-16 agonists also suggests several other nicotine alkaloids as leads for further development.
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Appendix A. Supplementary data {#appsec1}
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The following is the supplementary data related to this article:

Fig. S1NMR spectra for prepared (S)-*tert*-butyl 2-(5-bromopyridin-3-yl)piperidine-1-carboxylate.

Fig. S2NMR spectra for prepared (S)-5-bromoanabasine.

Fig. S3NMR spectra for prepared (S)-5-ethynyl-anabasine.

Fig. S4Sequence alignment between *Asu-*ACR-16 and its homologous proteins.

\(A\) Sequence and numbering of the ECD-*Asu*-ACR-16 (SwissProt ID: F1KYJ9) and its alignment with the *Lst*-AChBP (SwissProt ID: P58154). Completely conserved residues (red) and partially conserved residues (yellow) were indicated. Residues in the ligand-binding site of the principal subunit (pink arrow) were highly conserved, while the residues in the ligand-binding site of the complementary subunit of (purple arrow) were variable between *Asu-*ACR-16 and *Lst*-AChBP subunit. (B) Sequence and numbering of the ECD of human α7 nAChR chimera (PDB code: [3SQ6](pdb:3SQ6){#intref0025}) and its alignment with the ECD of human α7 nAChR (SwissProt ID: P36544). Completely conserved residues (red) and partially conserved residues (yellow) were indicated. Residues in the ligand-binding site of the principal subunit (pink) and residues in the ligand-binding site of the complementary subunit (purple) were highlighted by arrows. Except T150 on (+) and L106 on (−) of human α7 nAChR chimera are different with S172 on (+) and N129 on (−) of human α7 nAChR, the rest of interacting residues in human α7 nAChR chimera and human α7 nAChR were identical.

Fig. S5Docking results of nicotine and five top ligands in the agonist-bound *Asu*-ACR-16 model. Residues interacting with ligand (orange and white) are represented as sticks ((+), pink; (−), purple), and water molecule is shown as red dot.

Fig. S6Sample concentration response traces for other nicotine derivatives on the *Asu*-ACR-16 receptor. (S)-anabasine (A), (S)-5-bromonicotine (B), 6-methylnicotine (C), (S)-nicotine (D), ACh (E), (S)-1'-methylnicotinium (F), (S)-nicotine-5-carboxaldehyde (G), 6-AN (H), homonicotine (I), nornicotine (J) and (S, R)-anabasine (K) are depicted. For experiment of each nicotine derivative, one oocyte was used as a group. Five replicates were performed for each group. Resting membrane potential clamped at −60 mV. Downward responses to exposure of the agonists show opening of the ion-channel. Peak responses were recorded, normalized and fitted into the Hill equations.

Fig. S7Pharmacological profiles of (S)-anabasine and its racemic mixture. For each experiment, one oocyte was used as a group. Five replicates were performed for each group. Resting membrane potential clamped at −60 mV.

\(A\) Dose-response curves of (S)-anabasine (blue) and (S, R)-anabasine (dark yellow) for *Asu*-ACR-16. Response of 100 μM (S, R)-anabasine was shown but not fitted into its stimulatory dose-response plot due to its inhibitory effect. (B) Bar chart representing the *EC*~*50*~ and *I*~max~ (mean ± S.E.M, μM) of (S)-anabasine and its racemic mixture in (A). Significance was determined by un-paired student *t-*test. (S)-anabasine (1.26 ± 0.19 μM, *N* = 5) \< (S, R)-anabasine (2.03 ± 0.08 μM, *N* = 5), \*\**P* \< 0.01. (S)-anabasine (84.82 ± 4.20%, *N* = 5) ≈ (S, R)-anabasine (79.56 ± 2.24%, *N* = 5), *P* \> 0.05.

This research was supported by the Iowa State University startup to BV, NIH R21AI121831-01 to APR, NIH R01AI047194 to RJM.

Supplementary data related to this article can be found at [http://dx.doi.org/10.1016/j.ijpddr.2016.12.001](10.1016/j.ijpddr.2016.12.001){#intref0030}.

![Crystal structure of *Lst*-AChBP bound with nicotine (PDB code: [1UW6](pdb:1UW6){#intref0035}) and the agonist-bound model of *Asu*-ACR-16.\
(A) Ribbon diagram of the AChBP co-crystalized with nicotine, as viewed with membrane at the bottom. The principal subunit is highlighted by light pink and the complement subunit is highlighted by light purple, for clarity. Nicotine (orange) is bound in the five ligand-binding sites in the extracellular domain of AChBP.\
(B) Close view of the AChBP ligand-binding site. The principal subunit in light pink, the complementary subunit in light purple. Residues interacting with nicotine (orange) are represented as sticks ((+), pink; (−), purple), and water molecule is shown as red dot, view with membrane at the bottom.\
(C) Close view of the agonist-bound model of *Asu*-ACR-16 ligand-binding site. The principal subunit in light pink, the complementary subunit in light purple. The interacting residues are represented as sticks ((+), pink; (−), purple), and water molecule is shown as red dot, view with membrane at the bottom. (D) Superposition of residues in agonist-binding site, among agonist-bound form (blue), apo (no ligand) form (yellow), antagonist-bound form (green) of *Asu*-ACR-16 models are shown. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)](gr1){#fig1}

![Ligand-binding sites of *Asu*-ACR-16 and its homologous proteins.\
(A) Surface representation in the open-up ligand-binding site of *Lst*-AChBP in complex with nicotine (PDB code: [1UW6](pdb:1UW6){#intref0040}). Oxygen-rich area (red), nitrogen-rich area (blue) and carbon-rich area (gray) are displayed. Empty space was observed around the 5-pyridine ring of nicotine, which suggests that the ligand-binding site is in favor of the linear functional group linking toward the 5-pyridine ring of nicotine. Little space is found around the pyrrolidine ring of nicotine.\
(B) Surface representation in the open-up ligand-binding site of human α7 AChR chimera in complex with epibatidine (PDB code: [3SQ6](pdb:3SQ6){#intref0045}), viewed by the same angle as (A). Oxygen-rich area (red), nitrogen-rich area (blue), carbon-rich area (pink) and chloride (green) are displayed. The azabicyclic ring N1 of epibatidine was superimposed with the pyrrolidine ring N2 of nicotine, while the pyridine ring N2 of epibatidine was superimposed with the pyridine ring N1 of nicotine.\
(C) Surface representation in the open-up ligand-binding site of agonist-bound *Asu*-ACR-16 model, viewed by the same angle as (A). Oxygen-rich area (red), nitrogen-rich area (blue) and carbon-rich area (cyan) are displayed. Assuming the nicotine has the same binding pose as in (A) within the agonist-bound *Asu*-ACR-16, empty space around the 5-pyridine ring and pyrrolidine ring of nicotine, which allows nicotinic derivatives with modification in these positions fit into to the binding site. The black arrow indicates the likely orientation of the 5-pyridine ring moiety. (D) Surface representation in the open-up ligand-binding site of apo form *Asu*-ACR-16 model, viewed by the same angle as (A). Oxygen-rich area (red), nitrogen-rich area (blue) and carbon-rich area (yellow) are displayed. Assuming the nicotine has the same binding pose as in (A) within apo form *Asu*-ACR-16, there would be empty space around the 5-pyridine ring and pyrrolidine ring of nicotine, which would make the nicotinic derivatives with modification in these positions fit in the binding site. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)](gr2){#fig2}

![Chemical structures of (S)-nicotine and fifteen derivatives studied. 5-substituted pyridine ring derivatives: (S)---SIB 1508Y, (S)-5-bromonicotine, (S)-nicotine-5-carboxaldehyde and 5-methylnicotine; other pyridine ring substituted derivatives: (S)-1-methylnicotinium, 6-methylnicotine and 5-(1-methyl-pyrrolidin-2-yl)-pyridin-2-ylamine (6-AN); pyrrolidine ring substituted derivatives: (S)-1'-methylnicotinium, homonicotine, nornicotine and (S)-cotinine; piperidine ring derivatives: (S)-5-ethynyl-anabasine, (S)-5-bromoanabasine, (S)-anabasine and N-methyl anabasine are shown.](gr3){#fig3}

![Sample concentration-current recording traces for the most potent nicotine derivatives on the *Asu*-ACR-16 receptor. (S)-5-ethynyl-anabasine (A), (S)-5-bromoanabasine (B), (S)---SIB 1508Y (C), 5-methylnicotine (D) are depicted. For each nicotine derivative, 5 oocyte were tested as replicates. Resting membrane potential clamped at −60 mV. Downward responses to exposure of the agonists show opening of the ion-channel. Peak responses were recorded, normalized and fitted into the Hill equations.](gr4){#fig4}

![Dose-response curves of nicotine derivatives for *Asu*-ACR-16. For experiment of each nicotine derivative, one oocyte was used as a group. Five replicates were performed for each group. Current responses are normalized to the first 100 μM control application (Methods).\
(A) ACh and (S)-nicotine as two controls.\
(B) Pyridine ring substituted derivatives. Responses of 30 μM 5-methylnicotine and 100 μM 6-methylnicotine are shown but were not included for fitting the Hill equation to estimate *EC*~*50*~, *n*~*H*~*and I*~max~ correspondingly due to their inhibitory effects at high concentrations.\
(C) Pyrrolidine ring substituted derivatives. Response of 300 μM homonicotine is shown but was not included for fitting the Hill equation to estimate *EC*~*50*~, *n*~*H*~*and I*~max~ due to its inhibitory effect at high concentration.](gr5){#fig5}

![Correlations between binding affinities (kcal/mol) of each derivative in the apo form *Asu-*ACR-16 and *EC*~*50*~ (μM) (A), binding affinities (kcal/mol) for the selected nicotine derivatives. The correlation coefficients (r) was used for evaluating the linear regression between affinities and pharmacological parameters (r = 0.66, *P* \< 0.05).](gr6){#fig6}

###### 

Structural information for the ECD-*Asu-*ACR-16 and two of its homologous proteins (human α7 nAChR chimera and *Lst-*AChBP).

Table 1

  protein      Organism              PDB code         Resolution ($\mathsf{Å}$)   Ligand        Pharmacology
  ------------ --------------------- ---------------- --------------------------- ------------- --------------
  ECD-ACR-16   *Ascaris suum*                                                                   
  α7 nAChR     *Homo sapiens &*      3SQ6             2.8                         epibatidine   agonist
  chimera      *Lymnaea stagnalis*   3SQ9             3.1                         none          none
  4HQP         3.51                  α-bungarotoxin   antagonist                                
  AChBP        *Lymnaea stagnalis*   1UW6             2.2                         nicotine      agonist

###### 

Pharmacological profiles of ACh, nicotine and fifteen nicotine derivatives. Results (mean ± S.E.M.) were expressed as the *EC*~*50*~ (μM), Hill slope (*n*~*H*~*)* and maximum response (*I*~max~, %), number of repeats of each agonist experiment (*N*~*agonist*~). One oocyte was used in each replicate of experiment.

Table 2

  No:   Compound name                   EC~50~ (μM)    n~H~           I~max\ (%)~    N~agonist~
  ----- ------------------------------- -------------- -------------- -------------- ------------
  1:    (S)-5-ethynyl-anabasine         0.14 ± 0.01    1.81 ± 0.24    79.33 ± 3.75   5
  2:    (S)-5- bromoanabasine           0.32 ± 0.03    4.19 ± 1.58    80.69 ± 2.87   5
  3:    (S)eSIB 1508Y                   0.37 ± 0.10    0.94 ± 0.04    100.1 ± 4.36   5
  4:    5-methylnicotine                0.99 ± 0.17    2.09 ± 0.14    76.05 ± 1.22   5
  5:    (S)-anabasine                   1.26 ± 0.19    2.26 ± 0.20    84.82 ± 4.20   5
  6:    (S)-5-bromonicotine             2.04 ± 0.12    2.46 ± 0.21    69.66 ± 3.28   5
  7:    6-methylnicotine                6.13 ± 0.53    3.25 ± 0.24    69.74 ± 1.56   5
  8:    (S)-nicotine                    6.21 ± 0.56    3.39 ± 0.36    82.39 ± 2.52   5
  9:    ACh                             6.36 ± 0.49    2.93 ± 0.13    97.42 ± 0.93   5
  10:   (S)-1'- methylnicotinium        10.25 ± 0.62   3.52 ± 0.26    93.38 ± 5.25   5
  11:   (S)-nicotine-5-carboxaldehyde   11.51 ± 0.63   8.61 ± 4.04    62.20 ± 6.80   5
  12:   6-AN                            12.18 ± 0.29   10.10 ± 0.15   6.29 ± 0.62    5
  13:   homonicotine                    16.62 ± 1.44   6.78 ± 2.50    22.01 ± 1.39   5
  14:   nornicotine                     25.73 ± 4.71   3.25 ± 0.49    62.64 ± 3.42   5
  15:   N-methyl anabasine              \<100                                        
  16:   (S)-1- methylnicotinium         \<100                                        
  17:   (S)-cotinine                    \<100                                        
